Adalimumab-adbm Kit
Product Images NDC 0597-0555

Product Visual Gallery

This gallery contains 39 technical images submitted to the FDA as part of the official labeling for Adalimumab-adbm (NDC 0597-0555). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Adalimumab 01)

A line graph comparing the percent of ACR 20 responders over time in weeks between two groups: one receiving 40 mg of Adalimumab-adbm every other week and the other receiving a placebo. The graph shows higher response rates in the treatment group consistently across the 48-week period.*

FDA Label Image

Figure 2 (Adalimumab 02)

A line graph showing the percentage of ASAS 20 response over time in weeks for Adalimumab and placebo groups. The x-axis represents time in weeks from 0 to 26, and the y-axis shows the percentage response from 0 to 70%. The Adalimumab group (N=208) maintains a higher response rate compared to the placebo group (N=107) throughout the study period.*

FDA Label Image

Figure 3 (Study UV I)

A line graph comparing treatment failure rates over time in months between placebo and Adalimumab treatments. The y-axis shows treatment failure rate percentage, and the x-axis shows time in months up to 20. The placebo group has a higher failure rate trend than the Adalimumab group. The graph includes patient numbers at risk below the x-axis for both treatments at specific timepoints.*

FDA Label Image

Figure 3 (Study UV II)

A line graph comparing treatment failure rates over time (months) between placebo and Adalimumab in a clinical study. The vertical axis shows treatment failure rate percentages, and the horizontal axis shows time in months. Two curves represent placebo and Adalimumab groups with patient counts noted below the time axis at various intervals.*

FDA Label Image

Image (Adalimumab 05)

FDA Label Image

Image (Adalimumab 06)

An instructional diagram of a medication injection pen from the Adalimumab-adbm kit. The labeled parts include the injection button, grip, medicine window, tip with needle guard, cap, and the internal plunger. The image provides a clear layout of the pen's components to aid user understanding.*

FDA Label Image

Step 1 (Adalimumab 07)

Illustration showing four components of a medication kit labeled a through d: a pen-style injector device (a) containing medication, a red sharps disposal container with a biohazard symbol (b), and two types of wipes or pads (c and d) presumably for cleaning or preparing the injection site. The image likely relates to the handling and disposal of Adalimumab-adbm KIT components.*

FDA Label Image

Step 2 (Adalimumab 08)

An instructional illustration showing a medicine pen device with emphasis on the medicine inside and the location of the expiration date. The expiration date is depicted as 'EXP MMMYYYY' on the device label, indicating where to find this information. The medicine inside the pen is also highlighted.*

FDA Label Image

Step 3 (Adalimumab 09)

Illustration showing hands being washed with soap and water, demonstrating proper hand hygiene technique. The image highlights soap bubbles on the hands under running water from a faucet.*

FDA Label Image

Step 4 (Adalimumab 10)

Illustration showing recommended injection sites for Adalimumab-adbm, including the abdomen and thighs on a seated person, with these areas indicated by dotted circles.*

FDA Label Image

Step 5 (Adalimumab 11)

An instructional illustration showing a hand holding a small white square patch and placing it on the skin, indicated by a dashed circle. The image likely demonstrates the application of a transdermal or skin patch related to the Adalimumab-adbm kit.*

FDA Label Image

Step 6 (Adalimumab 12)

An instructional illustration showing two hands, one holding a green tube with a label, the other removing a small cap from the tube's nozzle. The image suggests preparation steps for using the product, Adalimumab-adbm kit, likely before administration.*

FDA Label Image

Step 7 (Adalimumab 13)

An instructional illustration showing a hand squeezing the skin around an injection site on an arm. The diagram includes a label identifying the area as 'Squeeze around injection site,' demonstrating proper technique for administering an injection.*

FDA Label Image

Step 8 (Adalimumab 14)

An instructional illustration demonstrating the proper technique for using the Adalimumab-adbm injection kit. It shows a hand holding the injector pen at a 90-degree angle to the skin surface, with a close-up inset emphasizing the need to press and hold the tip firmly against the skin during administration.*

FDA Label Image

Step 9 (Adalimumab 15)

An instructional illustration showing a hand holding an injection pen pressed against skin with the other hand supporting. Text instructs to press the injection button and hold the pen against squeezed skin while slowly counting to 10. A close-up inset highlights the plunger of the pen, demonstrating its movement during injection.*

FDA Label Image

Step 10 (Adalimumab 16)

An instructional illustration showing a hand holding an Adalimumab-adbm pen injector against an arm. The image includes a close-up inset demonstrating how to align the pen injector tip for proper injection. This instructional diagram depicts correct use of the Adalimumab-adbm kit for self-injection.*

FDA Label Image

Step 10 (Adalimumab 17)

An illustration depicting a hand pressing or holding a piece of soft material, possibly cotton or gauze, on a flat surface. The image appears instructional, likely showing a step in handling or applying a product related to Adalimumab-adbm kit use.*

FDA Label Image

Step 11 (Adalimumab 18)

An illustration showing a hand disposing of a used prefilled injection pen into a red biohazard sharps container with a top opening, indicating proper disposal of medical sharps waste.*

FDA Label Image

Image (Adalimumab 19)

FDA Label Image

Image (Adalimumab 20)

An instructional diagram illustrating the parts of an injection device, labeled as plunger rod, grip, plunger, medicine, needle, and cap. The image shows the components of a syringe or injector in a disassembled view.*

FDA Label Image

Step 1 (Adalimumab 21)

An instructional illustration showing components of the Adalimumab-adbm kit. It includes (a) a prefilled syringe with green finger grips, (b) a red biohazard sharps disposal container, (c) a cotton ball, and (d) an alcohol prep pad, all typically used for medication preparation and injection.*

FDA Label Image

Step 2 (Adalimumab 22)

An instructional diagram illustrating a syringe with the medicine inside and a magnified view highlighting where to find the expiration date on the syringe, showing format as month and year along with EXP and Lot information.*

FDA Label Image

Step 3 (Adalimumab 23)

An instructional illustration showing hands being washed under running water with soap bubbles visible, demonstrating proper handwashing technique.*

FDA Label Image

Step 4 (Adalimumab 24)

An instructional illustration showing recommended injection sites for the Adalimumab-adbm kit. The diagram labels the abdomen and thighs as suitable areas for injection on a seated person's body, with dotted circles indicating the specific injection sites.*

FDA Label Image

Step 5 (Adalimumab 25)

An instructional illustration showing a hand holding a small packet or wipe, positioned above a circular dotted area on the skin, indicating preparation or cleaning of the injection site, typically part of a self-injection or medication administration process.*

FDA Label Image

Step 6 (Adalimumab 26)

Illustration showing hands removing the protective cap from a syringe pen, depicted with an arrow indicating the direction of removal. The image demonstrates part of the preparation process for using an injection pen device, likely related to the administration of the drug kit.*

FDA Label Image

Step 7 (Adalimumab 27)

An instructional illustration showing a hand squeezing the skin around an injection site with a caption instructing to 'Squeeze around injection site and hold.' This diagram is likely part of usage instructions for the Adalimumab-adbm kit by Boehringer Ingelheim Pharmaceuticals, Inc.*

FDA Label Image

Step 8 (Adalimumab 28)

Illustration showing the proper technique for inserting a needle at a 45-degree angle into the skin, demonstrating hand positioning for injection.*

FDA Label Image

Step 9 (Adalimumab 29)

An instructional illustration showing how to slowly push the plunger rod of a syringe kit. It highlights the plunger component and demonstrates the action on a person's skin, indicating the proper technique for administering the injection.*

FDA Label Image

Step 10 (Adalimumab 30)

Illustration showing the removal of a needle from the skin at a 45-degree angle. It depicts a hand holding a syringe with the needle being withdrawn from an arm, accompanied by the instruction 'Remove needle.' This diagram aims to visually guide the correct needle removal technique.*

FDA Label Image

Step 10 (Adalimumab 31)

An illustration showing a hand holding a piece of cotton or gauze and pressing it against an arm, likely demonstrating a step in the preparation or administration of a drug injection.*

FDA Label Image

Step 11 (Adalimumab 32)

An instructional illustration showing a hand disposing of a used syringe into a red sharps disposal container marked with a biohazard symbol. The image emphasizes safe syringe disposal practices for Adalimumab-adbm kit users.*

FDA Label Image

Image (Adalimumab 33)

FDA Label Image

Principal Display Panel (40 mg/0.8 mL Kit Carton)

Packaging label for Adalimumab-adbm Injection 40 mg/0.8 mL. The kit contains 2 single-dose prefilled syringes for subcutaneous use only. The label features the Boehringer Ingelheim logo and indicates the product is a prescription drug. The label includes an image of a syringe with a green plunger cap and relevant regulatory and usage information.*

FDA Label Image

Principal Display Panel (20 mg/0.4 mL Kit Carton)

Packaging label for Adalimumab-adbm Injection, 20 mg/0.4 mL, a kit containing 2 single-dose prefilled syringes. Labeled for subcutaneous use only, this product is produced and labeled by Boehringer Ingelheim Pharmaceuticals, Inc. The label features a product image of the syringe and includes dosing and storage instructions.*

FDA Label Image

Principal Display Panel (10 mg/0.2 mL Kit Carton)

Carton packaging label for Adalimumab-adbm injection 10 mg/0.2 mL, a kit containing 2 single-dose prefilled syringes. The product is labeled for subcutaneous use only and is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. The label includes a size depiction of the syringe with a green plunger and a note indicating the needle cap contains dry natural rubber.*

FDA Label Image

Principal Display Panel (40 mg/0.8 mL Kit Carton)

Box packaging label for Adalimumab-adbm PEN injection, 40 mg/0.8 mL, for subcutaneous use only. The label shows 2 single-dose prefilled pens and is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. The label includes the product name, strength, dosage form (kit), and an image of the pen injector with a green grip.*

FDA Label Image

Principal Display Panel (40 mg/0.8 mL Kit Carton)

Packaging label for Adalimumab-adbm PEN injection, 40 mg/0.8 mL, a kit containing 4 single-dose prefilled pens. The label indicates subcutaneous use only and is designated as a starter package for psoriasis and uveitis. The labeler is Boehringer Ingelheim Pharmaceuticals, Inc., and the design features the product name, dosage strength, usage instructions, and an image of the prefilled pen with a green grip.*

FDA Label Image

Principal Display Panel (40 mg/0.8 mL Kit Carton)

Carton packaging label for Adalimumab-adbm PEN injection, 40 mg/0.8 mL, for subcutaneous use only. The label indicates a kit of 6 single-dose prefilled pens. It is labeled as a starter package for Crohn's disease, ulcerative colitis, or hidradenitis suppurativa. The carton includes branding for Boehringer Ingelheim Pharmaceuticals, Inc., and features an image of the injection pen with a green grip.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.